On the other hand, we also previously reported that higher circulating levels of the angiotensin-converting enzyme (ACE) is associated with a better response to anti-angiogenic treatment with bevacizumab in breast- and colorectal-cancer patients [22]. Here, ACE is linked to colorectal cancer.